Loading...
Innoviva reported strong Q1 2023 results with significant revenue from royalties and product sales. Net income increased to $34.9 million, and the company repurchased $40.3 million in common stock and paid off $96.2 million in convertible notes.
Received $60.3 million in GSK royalties, $11.5 million in net product revenues, and $8.0 million in license revenue.
Repurchased $40.3 million of common stock and paid off $96.2 million of 2023 convertible notes.
Net income was $34.9 million, or $0.51 basic per share.
Cash and cash equivalents totaled $144.0 million.
Analyze how earnings announcements historically affect stock price performance